
This meta-analysis evaluates the efficacy of myo-inositol supplementation in treating gestational diabetes. Four randomized controlled trials (RCTs) with 317 patients were included. Results show that myo-inositol supplementation significantly reduces the need for insulin treatment and improves insulin resistance (HOMA-IR), but has no significant impact on birth weight, cesarean section rate, or the need for NICU care. Myo-inositol is effective in managing gestational diabetes-related metabolic issues.
Like
Save
Share